ABBV - ABBV アッヴィ ()

ABBVのニュース

   Pharmaceutical Giant Merck Challenges Inflation Reduction Act over Medicare Drug Pricing, Calls It ''Extortion''  2023/06/06 19:03:23 Benzinga
Merck & Co Inc (NYSE: MRK ) has reportedly filed a lawsuit against the U.S. government to halt implementing the Medicare drug price negotiation program outlined in the Inflation Reduction Act (IRA). Pfizer Inc''s (NYSE: PFE ) CEO Albert Bourla called U.S. plans to negotiate drug prices for its Medicare health program "negotiation with a gun to your head ." Bristol Myers Squibb & Co''s (NYSE: BMY ) Eliquis, Pfizer''s Ibrance, and AbbVie … Full story available on Benzinga.com
   AbbVie Inc. (ABBV) to Present at the Goldman Sachs 44th Annual Global Healthcare Conference  2023/06/06 13:07:38 Marijuana Stocks
AbbVie to Present at the Goldman Sachs 44th Annual Global Healthcare Conference AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 44th Annual Global Healthcare Conference on Wednesday, June 14, 2023. Robert A. Michael, vice chairman and president, Jeffrey R. Stewart, executive vice president, chief commercial officer and Roopal Thakkar, senior vice president, development and regulatory affairs and chief medical officer, will present at 10:00 a.m. Central time. A live audio webcast of the presentation will be accessible through AbbVie’s Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology and gastroenterology, in addition to products and services across our Allergan Aesthetics portfolio.
   AbbVie to Present at the Goldman Sachs 44th Annual Global Healthcare Conference  2023/06/06 12:00:00 PR Newswire
NORTH CHICAGO, Ill., June 6, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 44th Annual Global Healthcare Conference on Wednesday, June 14, 2023. Robert A. Michael, vice chairman and president, Jeffrey R. Stewart, executive vice president, chief commercial…
   IBM, CVX, or ABBV: Which Dividend Aristocrat Stock is the Most Compelling Pick?  2023/06/06 04:30:17 TipRanks
During these uncertain times, investors seek reliable dividend-paying companies that can generate stable income. Dividend aristocrats are companies…
   AbbVie Stock May Be Falling On Humira LOE - But Investors Shouldn''t Panic  2023/06/05 17:00:02 Seeking Alpha
AbbVie''s share price has been slipping as its globally best-selling drug Humira has lost US patent protection. See why ABBV remains a magnet for investor money.
   CHINOOK INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Chinook To Contact Him Directly To Discuss Their Options  2023/06/03 12:00:00 Kwhen Finance
   AbbVie’s Rinvoq for Crohn’s Disease to see rapid uptake by healthcare providers: GlobalData  2023/06/02 06:26:14 Express Pharma
It is expected that the prescribing patterns of Rinvoq by HCPs will follow an ongoing trend by gastroenterologists to be more aggressive when treating CD to slow or prevent the progression of the disease The post AbbVie’s Rinvoq for Crohn’s Disease to see rapid uptake by healthcare providers: GlobalData appeared first on Express Pharma .
   AbbVie, Amgen hit 52-week lows as Coherus unveils cheapest Humira version  2023/06/01 18:17:38 Seeking Alpha
AbbVie (ABBV), and Amgen (AMGN) reached 52-week lows Thursday after Coherus BioSciences (CHRS) announced plans to launch the cheapest version of Humira. Read more here.
   Why Is AbbVie Stock Trading Down Today?  2023/06/01 18:03:53 Benzinga
AbbVie Inc. (NYSE: Full story available on Benzinga.com
   Why AbbVie and Amgen Are Moving Lower Today  2023/06/01 16:50:20 The Motley Fool
An ultra-low-priced biosimilar may negatively impact both biotechs.
   AbbVie to Present at the Bank of America Securities Healthcare Conference  2023/05/02 12:00:00 PR Newswire
NORTH CHICAGO, Ill., May 2, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Bank of America Securities Healthcare Conference on Tuesday, May 9, 2023. Robert A. Michael, vice chairman and president, Scott Reents, executive vice president, chief financial officer, Jeffrey R….
   Vertex Pharmaceuticals Stock Is an Even Better Buy Now Thanks to AbbVie  2023/05/02 09:50:00 The Motley Fool
One big drugmaker''s pain translates into another big drugmaker''s gain.
   Check Out What Whales Are Doing With ABBV  2023/05/01 19:16:54 Benzinga
Someone with a lot of money to spend has taken a bullish stance on AbbVie (NYSE: ABBV ). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don''t know. But when something this big happens with ABBV, it often means somebody knows something is about to happen. So how do we know what this whale just did? Today, Benzinga ''s options scanner spotted 15 uncommon options trades for AbbVie. This isn''t normal. The overall sentiment of these big-money traders is split between 66% bullish and 33%, bearish. Out of all of the special … Full story available on Benzinga.com
   UBS maintains AbbVie at Neutral with a price target of $157.00  2023/05/01 17:41:37 Investing.com
https://www.investing.com/news/pro/abbvie-inc-receives-investment-bank-analyst-rating-update-3069320
   Abbvie, Bristol Myers competed with Merck in sale of Prometheus - report  2023/05/01 17:29:00 Seeking Alpha
Abbvie (ABBV) and Bristol-Myers Squibb (BMY) competed to takeover Prometheus Biosciences (RXDX), before Merck (MRK) won in its pursuit of the biotech company. The interest from…

calendar